Mark J. Ratain to Cytochrome P-450 CYP3A
This is a "connection" page, showing publications Mark J. Ratain has written about Cytochrome P-450 CYP3A.
Connection Strength
0.712
-
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct; 48(10):973-983.
Score: 0.157
-
In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. Xenobiotica. 2015; 45(11):990-8.
Score: 0.133
-
Are drug labels static or dynamic? Clin Pharmacol Ther. 2013 Sep; 94(3):302-4.
Score: 0.118
-
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J. 2009 Feb; 9(1):49-60.
Score: 0.084
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
Score: 0.080
-
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Nov; 54(5):377-84.
Score: 0.062
-
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec; 70(6):854-69.
Score: 0.024
-
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun 01; 13(11):3302-11.
Score: 0.019
-
Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos. 2007 Feb; 35(2):228-33.
Score: 0.018
-
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep; 32(9):930-6.
Score: 0.016